Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 11Adcetris

PharmaCompass

01

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 468

2018 Revenue in Millions : 387

Growth (%) : 21

blank

02

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 547

2019 Revenue in Millions : 477

Growth (%) : 15

blank

03

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 563

2020 Revenue in Millions : 524

Growth (%) : 16

blank

04

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 642

2021 Revenue in Millions : 563

Growth (%) : 14

blank

05

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 46

2022 Revenue in Millions : 0

Growth (%) : Acquired from Seagen

blank

06

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 698

2022 Revenue in Millions : 641

Growth (%) : 23

blank

07

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 851

2023 Revenue in Millions : 695

Growth (%) : 22

blank

08

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2024 Revenue in Millions : 1,089

2023 Revenue in Millions : 56

Growth (%) : 1,845

blank

09

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2016 Revenue in Millions : 253

2015 Revenue in Millions : 242

Growth (%) : 4

blank

10

Brand Name : Adcetris

Brentuximab Vedotin

arrow
BIO Asia-Taiwan
Not Confirmed

Brand Name : Adcetris

arrow
BIO Asia-Taiwan
Not Confirmed

Brentuximab Vedotin

Main Therapeutic Indication : Oncology

Currency : USD

2017 Revenue in Millions : 357

2016 Revenue in Millions : 270

Growth (%) : 32

blank